We chose the APOE∗3-Leiden.CETP mouse model of hyperlipidemia to test NYX-PCSK9i efficacy as it is representative of human lipoprotein metabolism with respect to plasma lipoprotein levels, lipoprotein profiles, and has also been shown to be responsive to lipid-modulating drugs currently used in the clinic (42). Here, CETP is linked to hyperlipidemia.